$9.42
-0.53 (-5.33%)
Open$9.77
Previous Close$9.95
Day High$9.77
Day Low$8.91
52W High$309.60
52W Low$8.29
Volume—
Avg Volume160.6K
Market Cap60.64M
P/E Ratio—
EPS$-28.33
SectorBiotechnology
Analyst Ratings
Buy
13 analysts
Price Target
+191.0% upside
Current
$9.42
$9.42
Target
$27.41
$27.41
$18.46
$27.41 avg
$44.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 109.23M | 95.94M | 101.30M |
| Net Income | -383,926,522 | 13.15M | 13.02M |
| Profit Margin | -351.5% | 13.7% | 12.9% |
| EBITDA | -384,679,658 | 20.01M | 19.52M |
| Free Cash Flow | — | 11.25M | 11.45M |
| Rev Growth | — | +8.6% | -0.1% |
| Debt/Equity | 6.70 | 1.02 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |